The toolbox for treating COVID-19, hardly robust as is, became a little smaller thanks to an action today by the Food and Drug Administration. Hydroxychloroquine had received an emergency use authorization (EUA) in March after anecdotal data suggested therapeutic value in treating serious cases of the pandemic. Now that a clinical trial has shown no preventive benefit, and other data suggests no therapeutic benefit either, the FDA has pulled the EUA.
But did they act precipitately before — or are they acting precipitately now? After all, clinical studies on therapeutic use are still continuing, and this order does nothing to end them: